Repatha patent timelines?

Here’s a concise overview of Repatha (evolocumab) patent timelines, focused on the US and Europe, with notes on what can extend or delay expiry.

Key milestones
- Target discovery and early development
- 2000s: PCSK9 identified as a key regulator of LDL receptors; Amgen and collaborators begin developing anti-PCSK9 antibodies.
- Core patent filings (composition-of-matter and antibody patents)
- Late 2000s to early 2010s: Primary patent families covering evolocumab itself (the antibody) and other anti-PCSK9 antibodies are filed.
- FDA approval and market entry
- September 2015: Evolocumab (Repatha) approved by FDA for lowering LDL-C (initial indications in cardiovascular risk management).
- Follow-on patents and extensions
- 2015–2020s: Additional patents issued around dosing regimens, methods of use (e.g., combinations with statins), formulations, and possibly specific antibody variants or sequences. These extend exclusivity in certain jurisdictions beyond the core composition-of-matter patent.
- Expiry considerations
- Core “composition of matter” patents for evolocumab typically would have expired about a decade after the earliest filing, but term adjustments, pediatric extensions, and additional continuation patents can push some protection into the late 2020s or early 2030s in the US.
- In Europe, patent term and supplementary protection certificates (SPCs) can yield a similar extension pattern; data exclusivity and regulatory exclusivity may also influence market protection.
- Biosimilars landscape
- As of 2024, there were no FDA-approved evolocumab biosimilars in the US. EU activity has included development of biosimilars; patent expiry and market entry timelines for biosimilars vary by country and litigation outcomes.

What this means in practice
- If you’re asking about when generics or biosimilars could enter, the core composition-of-matter protection is the main determinant, but USPTO/EP patents often have multiple families with potential extensions via continuations and method-of-use claims.
- Exact expiry dates depend on:
- The specific patent family (composition of matter vs. method of use vs. formulation)
- Patent term adjustments and any pediatric/other regulatory extensions
- Any ongoing patent litigation or settlements
- Regulatory exclusivities (in the US, for example, data exclusivity) that can affect market entry timing

Want me to pull current, precise dates and patent numbers?
- I can look up the Evolocumab patent families (US and EU) on Google Patents or the USPTO/EPO databases and provide a clear list of:
- Key US and EU patent families (composition of matter, indications, dosing)
- Estimated expiry dates for each family (including any extensions)
- Any known litigation or settlements that affect timelines

If you tell me whether you want US-only, EU-only, or global, I’ll fetch and summarize the latest patent status for that scope.